JPMorgan lowered the firm’s price target on Xencor (XNCR) to $18 from $20 and keeps an Overweight rating on the shares following the Q3 report.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor Reports Improved Q3 2025 Financial Results
- Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating
- Promising Developments in Xencor’s Oncology and Autoimmune Pipelines Justify Buy Rating
- Xencor reports Q3 EPS (8c), consensus (70c)
- Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner